Catalyst
Slingshot members are tracking this event:
Rigel's Phase 3 Data for Two Fostamantanib Studies Aimed at Treating Immune Thrombocytopenic Purpura Expected August, October of 2016
- Source Link:
- http://www.biopharmcatalyst.com/fda-calendar/
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
RIGL |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 30, 2016
Occurred Source:
http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2198145
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Itp, Phase 3 Data